Clinical trial
Trastuzumab in Treating Patients With Recurrent Osteosarcoma
NCT00005033 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005033 |
|---|---|
| Title | Trastuzumab in Treating Patients With Recurrent Osteosarcoma |
| Official title | Phase II Study of Recombinant Humanized Monoclonal Antibody Against HER2 for the Treatment of Recurrent Osteosarcoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological, Procedure |
| Interventions | trastuzumab, conventional surgery |
| Start date | Dec 1, 1999 |
| Completion | Aug 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: